gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1475Research ArticleГЕПАТОЛОГИЯHEPATOLOGYВлияние полиморфизма интерлейкина 28В на раннюю кинетику HCV у больных, получающих противовирусную терапию после ортотопической трансплантации печениInterleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapyСюткинВ. Е.SyutkinV. E.ЧулановВ. П.ChulanovV. P.КарандашоваИ. В.KarandashovaI. V.ДолгинВ. А.DolginV. A.ЧугуновА. О.ChugunovA. O.2011251220112164955Copyright © Сюткин В.Е., Чуланов В.П., Карандашова И.В., Долгин В.А., Чугунов А.О., 20112011Сюткин В.Е., Чуланов В.П., Карандашова И.В., Долгин В.А., Чугунов А.О.Syutkin V.E., Chulanov V.P., Karandashova I.V., Dolgin V.A., Chugunov A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1475

Цель исследования. Изучить влияние генотипа ИЛ-28В реципиента на быстрый (БВО) и ранний (РВО) вирусологический ответы у реципиентов печени, получающих противовирусную терапию (ПВТ) по поводу гепатита С.Материал и методы. Однонуклеотидные замены в области гена ИЛ-28В (rs8099917 и rs12979860) изучены в мононуклеарах крови 24 реципиентов печени, инфицированных HCV, которые получали ПВТ пегилированным интерфероном альфа с рибавирином (n=21) или без рибавирина (n=3).Результаты. У 5 пациентов наблюдался БВО, еще у 10 – полный РВО. В 6 случаях авиремия получена только к 24-й неделе ПВТ, т. е. наблюдался медленный вирусологический ответ (МВО). Три пациента не ответили на ПВТ. G-аллель (rs80999917) выявлялся у 3 (20%) из 15 пациентов с полным РВО и у 5 из 6 с МВО (p=0,014). Генотип C/C (rs12979860) обнаружен у 6 (40%) больных с полным РВО и ни в одном случае при МВО (p=0,04). Группы реципиентов с и без полного РВО были сопоставимы по полу, возрасту, виремии до начала ПВТ, иммуносупрессии (циклоспорин или такролимус), массе тела и индексу массы тела, средней дозе рибавирина. Единственными факторами, влиявшими до начала ПВТ на полный РВО, были генотип HCV (1/не-1) и полиморфизм гена ИЛ-28В.Заключение. Полиморфизм ИЛ-28В является важным прогностическим фактором МВО у инфицированных HCV реципиентов печени и должен учитываться при планировании длительности ПВТ после трансплантации печени.

Aim

Aim. To estimate the impact of recipient IL28B genotypes on rapid (RVR) and early virologic responses (EVR) pattern in liver transplant recipients undergoing antiviral treatment (AVT).

Material and methods

Material and methods. Blood samples were screened for single nucleotide polymorphisms (SNP) near the IL28B genes (rs8099917 T ≥G and rs12979860 C>T) by kit «AmpliSens® Genoscreen-IL28B-FL» (CRIE) in 24 HCV-infected recipients. All the patients underwent pegylated interferon-alfa with (n=21) or without (n=3) ribavirin at least for 12 weeks.

Results

Results. Five recipients achieved RVR (one has HCV genotype 1 and 4 patients – HCV genotype 2 or 3) and other 10 – complete EVR. In 6 cases slow virologic response (aviremia between 12 and 24 weeks of treatment, SlVR) occurred. Three patients remained non-responders. G-allele (rs80999917) was present in 3 (20%) out of 15 pts. with complete EVR and in 5 out of 6patients with SlVR (p=0.014). Genotype C/C (rs12979860) was present in 6 (40%) patients with complete EVR and in none of slow-responders (one-sided p=0.041).The groups of recipients with and without complete EVR were comparable with sex, age, pre-treatment viral load, immunosuppression (cyclosporine vs. tacrolimus), weight and body mass index, and mean ribavirin dose. The only pre-treatment factors which have impact on complete EVR were genotype (1 vs. non-1) and IL28B polymorphisms.

Conclusion

Conclusion. The SNP in IL28B region may predict slow response to AT in post-LTx setting and should be considered when AT duration is planning.

интерлейкин 28Впегилированный интерферонвирус гепатита Сранняя вирусная кинетикаinterleukin 28Вpegilated interferonhepatitis C virusearly viral kineticsReferencesСюткин В.Е. Новые возможности повышения эффективности противовирусной терапии больных хроническим гепатитом С // Инфекционные болезни. – 2009. – Т. 7, № 2. – P. 55–59.Сюткин В.Е. Новые возможности повышения эффективности противовирусной терапии больных хроническим гепатитом С // Инфекционные болезни. – 2009. – Т. 7, № 2. – P. 55–59.Afdhal N.H., McHutchison J.G., Zeuzem S. et al. Hepatitis C pharmacogenetics: state of the art in 2010 // Hepatology. – 2011. – Vol. 53, N 1. – P. 336–345.Afdhal N.H., McHutchison J.G., Zeuzem S. et al. Hepatitis C pharmacogenetics: state of the art in 2010 // Hepatology. – 2011. – Vol. 53, N 1. – P. 336–345.Charlton M.R., Thompson A., Veldt B.J. et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection // Hepatology. – 2011. – Vol. 53, N 1. – P. 317–324.Charlton M.R., Thompson A., Veldt B.J. et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection // Hepatology. – 2011. – Vol. 53, N 1. – P. 317–324.Coto-Llerena M., Perez-Del-Pulgar S., Crespo G. et al. Donor and recipient IL28B polymorphisms in HCVinfected patients undergoing antiviral therapy before and after liver transplantation // Am. J. Transplant. – 2011. – Vol. 11, N 5. – P. 1051–1057.Coto-Llerena M., Perez-Del-Pulgar S., Crespo G. et al. Donor and recipient IL28B polymorphisms in HCVinfected patients undergoing antiviral therapy before and after liver transplantation // Am. J. Transplant. – 2011. – Vol. 11, N 5. – P. 1051–1057.Dienstag J.L., McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C // Gastroenterology. – 2006. – Vol. 130, N 1. – P. 225–230.Dienstag J.L., McHutchison J.G. American Gastroenterological Association medical position statement on the management of hepatitis C // Gastroenterology. – 2006. – Vol. 130, N 1. – P. 225–230.Eurich D., Boas-Knoop S., Ruehl M. et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation // Liver Transpl. – 2011. – Vol. 17, N 3. – P. 289–298.Eurich D., Boas-Knoop S., Ruehl M. et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation // Liver Transpl. – 2011. – Vol. 17, N 3. – P. 289–298.Fukuhara T., Taketomi A., Motomura T. et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C // Gastroenterology. – 2010. – Vol. 139, N 5. – P. 1577–1585.Fukuhara T., Taketomi A., Motomura T. et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C // Gastroenterology. – 2010. – Vol. 139, N 5. – P. 1577–1585.Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. – 2009. – Vol. 461, N 7262. – P. 399–401.Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. – 2009. – Vol. 461, N 7262. – P. 399–401.Lange C.M., Moradpour D., Doehring A. et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection // J. Hepatol. – 2011. – Vol. 55, N 2. – P. 322-327.Lange C.M., Moradpour D., Doehring A. et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection // J. Hepatol. – 2011. – Vol. 55, N 2. – P. 322-327.Mangia A., Thompson A.J., Santoro R. et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response // Gastroenterology. – 2010. – Vol. 139, N 3. – P. 821–827.Mangia A., Thompson A.J., Santoro R. et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response // Gastroenterology. – 2010. – Vol. 139, N 3. – P. 821–827.Neumann A.U., Bibert S., Haagmans B.L. et al. DITTO-HCV Group. IL28B polymorphism is significantly correlated with IFN anti-viral effictiveness already on first day of pegylated interferon-A and ribavirin therapy of chronic HCV infection [Abstract 2011] // J. Hepatol. – 2010. – Vol. 52 (suppl. 1). – P. 468.Neumann A.U., Bibert S., Haagmans B.L. et al. DITTO-HCV Group. IL28B polymorphism is significantly correlated with IFN anti-viral effictiveness already on first day of pegylated interferon-A and ribavirin therapy of chronic HCV infection [Abstract 2011] // J. Hepatol. – 2010. – Vol. 52 (suppl. 1). – P. 468.Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study // Gastroenterology. – 2010. – Vol. 138, N 4. – P. 1338–1345.Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study // Gastroenterology. – 2010. – Vol. 138, N 4. – P. 1338–1345.Suppiah V., Moldovan M., Ahlenstiel G. et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy // Nat. Genet. – 2009. – Vol. 41, N 10. – P. 1100–1104.Suppiah V., Moldovan M., Ahlenstiel G. et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy // Nat. Genet. – 2009. – Vol. 41, N 10. – P. 1100–1104.Tanaka Y., Nishida N., Sugiyama M. et al. Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C // Nat. Genet. – 2009. – Vol. 41, N 10. – P. 1105–1109.Tanaka Y., Nishida N., Sugiyama M. et al. Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C // Nat. Genet. – 2009. – Vol. 41, N 10. – P. 1105–1109.Thompson A.J., Muir A.J., Sulkowski M.S. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus // Gastroenterology. – 2010. – Vol. 139, N 1. – P. 120–129.Thompson A.J., Muir A.J., Sulkowski M.S. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus // Gastroenterology. – 2010. – Vol. 139, N 1. – P. 120–129.Ueda Y., Takada Y., Marusawa H. et al. Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation // J. Viral. Hepatol. – 2010. – Vol. 17, N 7. – P. 481–487.Ueda Y., Takada Y., Marusawa H. et al. Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation // J. Viral. Hepatol. – 2010. – Vol. 17, N 7. – P. 481–487.

The authors declare that there are no conflicts of interest present.